about
Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphomaChemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin LymphomaChemotherapy, radiotherapy and combined modality for Hodgkin's disease, with emphasis on second cancer riskLow-dose (10-Gy) total skin electron beam therapy for cutaneous T-cell lymphoma: an open clinical study and pooled data analysis.Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin's lymphoma: a systematic review.Phase II study of docetaxel and cisplatin in patients with recurrent or disseminated squamous-cell carcinoma of the head and neck.Interfractional changes in tumour volume and position during entire radiotherapy courses for lung cancer with respiratory gating and image guidance.Construction of a pathological risk model of occult lymph node metastases for prognostication by semi-automated image analysis of tumor budding in early-stage oral squamous cell carcinoma.Long-term hospitalisation rates among 5-year survivors of Hodgkin lymphoma in adolescence or young adulthood: A nationwide cohort studyMethodologies for localizing loco-regional hypopharyngeal carcinoma recurrences in relation to FDG-PET positive and clinical radiation therapy target volumes.The role of miRNAs in human papilloma virus (HPV)-associated cancers: bridging between HPV-related head and neck cancer and cervical cancer.Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial.Human papillomavirus in head and neck squamous cell carcinoma of unknown primary is a common event and a strong predictor of survival.Cardiovascular disease after cancer therapy.Different miRNA signatures of oral and pharyngeal squamous cell carcinomas: a prospective translational study.Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin's Disease Collaborative Group.MiR-21 expression in the tumor stroma of oral squamous cell carcinoma: an independent biomarker of disease free survivalPrognostic factors in Hodgkin's disease.Molecular profiling of tumour budding implicates TGFβ-mediated epithelial-mesenchymal transition as a therapeutic target in oral squamous cell carcinoma.Recurrences after intensity modulated radiotherapy for head and neck squamous cell carcinoma more likely to originate from regions with high baseline [18F]-FDG uptakeFDG-PET in the clinical management of Hodgkin lymphoma.(18)F-FDG PET imaging in detection of radiation-induced vascular disease in lymphoma survivorsPositron emission tomography/computed tomography surveillance in patients with Hodgkin lymphoma in first remission has a low positive predictive value and high costs.Tumour burden in early stage Hodgkin's disease: the single most important prognostic factor for outcome after radiotherapy.Life years lost--comparing potentially fatal late complications after radiotherapy for pediatric medulloblastoma on a common scaleIncreasing incidence of base of tongue cancers from 2000 to 2010 due to HPV: the largest demographic study of 210 Danish patients.Reproducibility of (18)F-FDG PET uptake measurements in head and neck squamous cell carcinoma on both PET/CT and PET/MRInterobserver delineation variation in lung tumour stereotactic body radiotherapy.The role of image guidance in respiratory gated radiotherapy.Human papillomavirus and oropharyngeal cancer in Greenland in 1994-2010.First-in-man mesenchymal stem cells for radiation-induced xerostomia (MESRIX): study protocol for a randomized controlled trial.Risk factors for radiation-induced hypothyroidism: a literature-based meta-analysis.Radiotherapy studies and extra-nodal non-Hodgkin lymphomas, progress and challenges.Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG).Mesenchymal stem cell therapy for salivary gland dysfunction and xerostomia: a systematic review of preclinical studies.A decade of comparative dose planning studies for early-stage Hodgkin lymphoma: what can we learn?Increasing incidence and survival in oral cancer: a nationwide Danish study from 1980 to 2014.Phase I trial of 18F-Fludeoxyglucose based radiation dose painting with concomitant cisplatin in head and neck cancer.Spatio-temporal stability of pre-treatment 18F-Fludeoxyglucose uptake in head and neck squamous cell carcinomas sufficient for dose painting.Prescribing and evaluating target dose in dose-painting treatment plans.
P50
Q24236589-5201339D-AD2B-4E01-9CE0-24B6D1FCE4DEQ24243379-F827AE76-FA03-432D-8DEF-4F92F97071C4Q24245375-D8E44283-C60D-412C-9002-C131EF7E522EQ30929809-2E3762A5-6F45-40D9-A766-BCBB7018B118Q30937299-CAF9B92C-90D9-4112-9007-A39A15CCAF2EQ33334191-BBD4A563-FB57-4FE2-9D1F-872DB8E828B1Q33358426-FC8FCD9E-7A81-4B51-9CED-0D324134B030Q33566888-00F371AF-23FF-4BD5-938A-9AE3659F79F6Q33578319-93F506B9-B0F6-4901-8508-482257506597Q33689901-F98404DB-62EE-464F-B501-BB89ABF86FDDQ34219266-A2376A3F-9F5B-4948-A77B-B3D5BAB8FBE4Q34265391-4876C33B-B040-4CDE-BA99-61AB511931EBQ34450121-1A8AE816-4A5A-4B62-9517-15CD6BACBCB9Q34604429-7A32A7E0-E315-4DED-9C13-EC9AA73CA993Q34621889-9FFC8A42-0FC6-4B33-862C-E7957D4C6893Q34746225-AE82942F-D9C5-49A5-BABD-F8C36D58C577Q35155103-086CB7D7-E574-4EB3-BEE4-2E25D38175E1Q35483865-A0CEF59E-30F8-48C2-8FCD-84F969A33E1AQ35618225-D7E60388-5A31-478C-B980-847AD22BD55EQ35747345-E91E141D-0E59-4494-9AEF-C32B9078CE97Q35885314-9F71A874-776D-4E59-99B6-C70EDD135F41Q35929739-DA0B6545-7826-4C73-8117-7B53532CB29BQ36006435-762D34AA-5C22-4055-8D14-C91204ACF773Q36028083-20A794B5-5E17-4168-A627-4444B117B90BQ36110194-399C0E03-D2C9-4EBC-949B-1BCDD8542763Q36286630-9B77F675-0FF2-40A4-9727-2901C7B7E343Q36295389-50BB9515-CD43-45C7-AFFD-3CF52DBAEDF8Q36365506-1A8354BE-CEFF-4A2B-BA9C-40985F8E04E5Q37214729-76840C6B-1CFD-46F1-9AA7-CE6632EBF06DQ37289348-EC93C75F-144D-451B-AF57-B3B76C855A98Q37686456-EC3C83EA-CA59-49EA-A5B6-441A1DFD878AQ37874998-52B9DCDA-96AD-4BA4-B33D-7C97ADA53A71Q37994920-1A670BBB-EA84-45F4-9854-61DABCA08E07Q38116144-69ADF9FC-7FE3-4820-A33B-703A366A47E8Q38188093-8FE35F6B-623C-4FF8-999F-9879612DA1C7Q38300229-51593090-2729-4797-B472-9A913B0AF239Q38401834-4788B4B4-49BB-4102-A8DC-D39673C586DDQ38409078-0CD5A97E-5BF1-4F2A-A652-FC86A209A9DFQ38412675-8068394A-0053-41D1-8941-2C075008658DQ38420289-AA9370CD-C67C-4154-B4B3-CDA9D1F808B8
P50
description
hulumtuese
@sq
researcher
@en
ricercatrice
@it
wetenschapper
@nl
հետազոտող
@hy
name
Lena Specht
@ast
Lena Specht
@en
Lena Specht
@es
Lena Specht
@nl
Lena Specht
@sl
type
label
Lena Specht
@ast
Lena Specht
@en
Lena Specht
@es
Lena Specht
@nl
Lena Specht
@sl
prefLabel
Lena Specht
@ast
Lena Specht
@en
Lena Specht
@es
Lena Specht
@nl
Lena Specht
@sl
P214
P244
P106
P21
P213
0000 0001 0726 4904
P214
P244
nb2010029223
P31
P496
0000-0002-6902-2190
P5008
P734
P735
P7859
lccn-nb2010029223